1. Gut microbial and functional alterations lead to metagenomic signatures for midgut neuroendocrine tumor patients and for carcinoid syndrome.
- Author
-
Mulders MCF, Van Koetsveld PM, Feelders RA, Hofland LJ, de Herder WW, Kraaij R, and Hofland J
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Feces microbiology, Metagenome, Metagenomics methods, Prospective Studies, Gastrointestinal Microbiome genetics, Intestinal Neoplasms diagnosis, Intestinal Neoplasms genetics, Intestinal Neoplasms microbiology, Intestinal Neoplasms pathology, Malignant Carcinoid Syndrome diagnosis, Malignant Carcinoid Syndrome genetics, Malignant Carcinoid Syndrome microbiology, Malignant Carcinoid Syndrome pathology, Neuroendocrine Tumors diagnosis, Neuroendocrine Tumors genetics, Neuroendocrine Tumors microbiology, Neuroendocrine Tumors pathology
- Abstract
Midgut neuroendocrine tumors (NET) derive from enterochromaffin cells, which have a close interrelationship with intestinal microbiota. Recently, we have utilized 16S rRNA sequencing to uncover that midgut NET patients have a depleted gut microbiome and a specific fecal microbial signature. This study aims to validate these findings and to further characterize the role of microbes and microbial metabolic pathways in midgut NET patients with and without carcinoid syndrome (CS). Fecal samples from 60 midgut NET patients and 20 household-matched controls were subjected to whole metagenome sequencing. The gut microbial community composition of midgut NET patients differed from that of controls, with 2 genera, 17 species and 9 microbial pathways showing differential abundance (P < 0.001). No differences in the microbial composition were observed between midgut NET patients with and without CS (P > 0.05). However, we did observe changes in inter-genus correlations of Bacteroides, Odoribacter, Parasutterella, Klebsiella, Ruminococcus and Proteobacteria when comparing these two patient groups. A signature of 16 microbial species (area under the receiver operating characteristics (AUROC) curve 0.892) or 18 microbial pathways (AUROC 0.909) accurately predicted the presence of a midgut NET. Furthermore, a microbial signature consisting of 14 functional microbial pathways distinguished CS patients from non-CS patients (AUROC 0.807). Thus, this study confirms that the gut microbiome of midgut NET patients is altered at the metagenomic level, which is not related to the presence of CS. A fecal microbial signature could constitute a novel biomarker for the diagnosis of midgut NET or CS.
- Published
- 2025
- Full Text
- View/download PDF